Why ProQR Therapeutics’s Stock Is Trading Higher Today
ProQR Therapeutics's (NASDAQ:PRQR) shares are trading higher after the company announced Axiomer RNA editing licensing and research collaboration with Lilly.
35 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment.
Benzinga Pro’s Top 5 Stocks To Watch For Thursday, Sept. 9, 2021: ORCL, GME, HYZN, SAM, PRQR
Today's 5 Stock Ideas:
Oracle (ORCL) - Oracle reports Q1 earnings results on Monday, September 13th.
GameStop (GME) - Shares down ~11% premarket. The company reported Q2 earnings results
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
Eli Lilly Inks Another RNA Collab, This Time With ProQR
Eli Lilly And Co (NYSE:LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing…
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $18
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $20 to $18.
